Pharma giants shift focus towards biologics
Biopharmaceuticals and biologics in particular are coming into their own, according to the latest GBI Research report.
Large pharmaceutical companies are increasingly moving into the biologics arena, a new report has revealed.
Biologic therapies are associated with high costs and tend to be associated with very specific targets.
However, GBI Research's latest report claims that active pharmaceutical ingredient (API) revenues will be boosted over the coming years by increased uptake of biologics across various therapeutic areas.
According to the research firm, many multinational pharmaceutical companies have chosen "to shift their focus towards biologics manufacturing, either through subsidiaries or by outsourcing to specialised companies, as the acceptance rate for biologics increases across the globe, justifying the high financial commitment".
The report also states that while synthetic API revenues accounted for 82.7 per cent of the global API market in 2001, biopharmaceuticals are starting to challenge synthetics' market dominance.
Biotech API revenues grew at a compound annual growth rate (CAGR) of 17.4 per cent between 2005 and 2011, while the global API market as a whole is expected to increase at a CAGR of 7.4 per cent between 2011 and 2017.
Related News
-
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. -
Sponsored Content CPHI Online Trend Report: How can flow chemistry help businesses achieve their sustainability goals?
In our latest CPHI Online Trend Report, we partner with Asymchem to understand the innovative potential of flow chemistry for API manufacturing, especially in regards to meeting sustainability goals.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance